Leukemia and lymphoma of natural killer lineage cells

International Journal of Hematology

Volumn 78, Issue 1, 2003, Pages 18-23

  Oshimi, Kazuo ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Leukemia; Lymphoma; NK cell

Indexed keywords

CD3 ANTIGEN; CD56 ANTIGEN;

ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; BLASTIC NATURAL KILLER CELL LYMPHOMA; CELL LINEAGE; CELL STRUCTURE; CHRONIC NATURAL KILLER CELL LYMPHOCYTOSIS; CLINICAL FEATURE; CYTOTOXICITY; GERM LINE; HUMAN; LEUKEMIA; LYMPHOCYTE; LYMPHOCYTOSIS; LYMPHOMA; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MYELOID LEUKEMIA; MYELOID NATURAL KILLER CELL PRECURSOR ACUTE LEUKEMIA; NASAL TYPE NATURAL KILLER CELL LYMPHOMA; NATURAL KILLER CELL; NATURAL KILLER CELL LEUKEMIA; NATURAL KILLER CELL LYMPHOMA; NATURAL KILLER CELL TUMOR; PHENOTYPE; PRECURSOR NATURAL KILLER CELL ACUTE LYMPHOBLASTIC LEUKEMIA; REVIEW; STEM CELL; T LYMPHOCYTE RECEPTOR GENE;

EID: 0042848524     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02983235     Document Type: Review

References (46)

1. Trinchieri G. Biology of natural killer cells. Adv Immunol. 1989;47:187-376.
2. Hercend T, Schmidt RE. Characteristics and uses of natural killer cells. Immunol Today. 1988;9:291-293.
3. Robertson MJ, Ritz J. Biology and clinical relevance of human natural killer cells. Blood. 1990;76:2421-2438.
4. Oshimi K. Lymphoproliferative disorders of natural killer cells. Int J Hematol. 1996;63:279-290.
5. Lanier LL, Spits H, Phillips JH. The developmental relationship between NK cells and T cells. Immunol Today. 1992;13:392-395.
6. Sanchez MJ, Muench MO, Roncarolo MG, Roncarlo MG, Lanier LL, Phillips JH. Identification of a common T/natural killer cell progenitor in human fetal thymus. J Exp Med. 1994;180:569-576.
7. Spits H, Lanier LL, Phillips JH. Development of human T and natural killer cells. Blood. 1995;85:2654-2670.
8. Spits H, Blom B, Jaleco A-C, et al. Early stages in the development of human T, natural killer and thymic dendritic cells. Immunol Rev. 1998;165:75-86.
9. Oshimi K. Provisional classification and diagnostic criteria of NK-cell tumors proposed by the NK-Cell Tumor Study Group [in Japanese]. Ketsueki-Schuyou-ka. 2000;40:87-88.
10. + myeloid/natural killer cell precursor acute leukemia: a distinct hematolymphoid disease entity. Blood. 1997;90:2417-2428.
11. Suzuki R, Nakamura S. Malignancies of natural killer (NK) cell precursor: myeloid/NK cell precursor acute leukemia and blastic NK cell lymphoma/leukemia. Leuk Res. 1999;23:615-624.
12. + phenotype and chromosome 5 abnormalities for acute myeloid leukemia MO. Int J Hematol. 2003;77:482-489.
13. Nakamura F, Tatsumi E, Kawano S, et al. Acute lymphoblastic leukemia/lymphoblastic lymphoma of natural killer (NK) lineage: quest for another NK-lineage neoplasm. Blood. 1997;89:4665-4666.
14. Chaperot L, Bendriss N, Manches O, et al. Identification of a leukemic counterpart of the plasmacytoid dendritic cells. Blood. 2001;97:3210-3217.
15. + malignancies. Blood. 2002;99:1556-1563.
16. + DC2 acute leukemia is characterized by recurrent clonal chromosomal changes affecting 6 major targets: a study of 21 cases by the Groupe Francais de Cytogenetique Hematologique. Blood. 2002;99:4154-4159.
17. Petrella T, Comeau MR, Maynadie M, et al. "Agranular CD4+ CD56+ hematodermic neoplasm" (blastic NK-cell lymphoma) originates from a population of CD56+ precursor cells related to plasmacytoid monocytes. Am J Surg Pathol. 2002;26:852-862.
18. Imamura N, Kusunoki Y, Kawa-Ha K, et al. Aggressive natural killer cell leukemia/lymphoma: report of four cases and review of the literature: possible existence of a new clinical entity originating from the third lineage of lymphoid cells. Br J Haematol. 1990;75:49-59.
19. Mori KL, Egashira M, Oshimi K. Differentiation stage of natural killer cell-lineage lymphoproliferative disorders based on phenotypic analysis. Br J Haematol. 2001;115:225-228.
20. Oshimi K, Yamada O, Kaneko T, et al. Laboratory findings and clinical courses of 33 patients with granular lymphocyte-proliferative disorders. Leukemia. 1993;7:782-788.
21. Yamamoto T, Iwasaki T, Watanabe N, et al. Expression of multidrug resistance P-glycoprotein on peripheral blood mononuclear cells of patients with granular lymphocyte-proliferative disorders. Blood. 1993;81:1342-1346.
22. Yamaguchi M, Kita K, Miwa H, et al. Frequent expression of P-glycoprotein/MDR1 by nasal T-cell lymphoma cells. Cancer, 1995;76:2351-2356.
23. Egashira M, Kawamata N, Sugimoto K, Kaneko T, Oshimi K. P-glycoprotein expression on normal and abnormally expanded natural killer cells and inhibition of P-glycoprotein function by cyclosporin A and its analogue, PSC833. Blood, 1999;93:599-606.
24. Trambas C, Wang Z, Cianfriglia M, Woods G. Evidence that natural killer cells express mini P-glycoproteins but not classic 170 kDa P-glycoprotein. Br J Haematol. 2001;114:177-184.
25. Wong KF, Zhang YM, Chan JKC. Cytogenetic abnormalities in natural killer cell lymphoma/leukaemia: is there a consistent pattern? Leuk Lymphoma. 1999;34:241-250.
26. Siu LLP, Wong K-F, Chan JKC, Kwong YL. Comparative genomic hybridization analysis of natural killer cell lymphoma/leukemia: recognition of consistent patterns of genetic alterations. Am J Pathol. 1999;155:1419-1425.
27. Siu LLP, Chan V, Chan JKC, Wong KF, Liang R, Kwong YL. Consistent patterns of allelic loss in natural killer cell lymphoma. Am J Pathol. 2000;157:1803-1809.
28. Wong KF. Genetic changes in natural killer cell neoplasms. Leuk Res. 2002;26:977-978.
29. Li T, Hongyo T, Syaifudin M, et al. Mutations in the p53 gene in nasal NK/T-cell lymphoma. Lab Invest. 2000;80:493-499.
30. Sakajiri S, Kawamata N, Egashira M, Mori K, Oshimi K. Molecular analysis of tumor suppressor genes, Rb, p53, p16INK4A, p15INK4B and p14ARF in natural killer cell neoplasms. Jpn J Cancer Res. 2001;92:1048-1056.
31. Sugimoto K, Kawamata N, Sakajiri S, Oshimi K. Molecular analysis of oncogenes, ras family genes (N-ras, K-ras, H-ras), myc family genes (c-myc, N-myc) and mdm2 in natural killer cell neoplasms. Jpn J Cancer Res. 2002;93:1270-1277.
32. Oshimi K. NK cell lymphoma. Int J Hematol. 2002;76(suppl 2): 118-121.
33. + T-cell receptor silent peripheral T-cell lymphomas are natural killer cell lymphomas. Blood. 1996;87:1466-1473.
34. Shikama N, Izuno I, Oguchi M, et al. Clinical stage IE primary lymphoma of the nasal cavity: radiation therapy and chemotherapy. Radiology. 1997;204:467-470.
35. Li Y-X, Coucke PA, Li J-Y, et al. Primary non-Hodgkin's lymphoma of the nasal cavity: prognostic significance of paranasal extension and the roles of radiotherapy and chemotherapy. Cancer. 1998;83:449-456.
36. Kim GE, Cho JH, Yang WL, et al. Angiocentric lymphoma of the head and neck: patterns of systemic failure after radiation treatment. J Clin Oncol. 2000;18:54-63.
37. Yamaguchi M, Ogawa S, Nomoto Y, et al. Treatment outcome of nasal NK-cell lymphoma: a report of 12 consecutively-diagnosed cases and a review of the literature. J Clin Exp Hematopathol. 2001;41:93-99.
38. Liang R, Todd D, Chan TK, et al. Treatment outcome and prognostic factors for primary nasal lymphoma. J Clin Oncol. 1995;13:666-670.
39. Cheung MMC, Chan JKC, Lau WH, et al. Primary non-Hodgkin's lymphoma of the nose and nasopharynx: clinical features, tumor immunophenotype, and treatment outcome in 113 patients. J Clin Oncol. 1998;16:70-77.
40. Kitoh T, Sawada M, Shirahase K, et al. Asparagine synthetase protein expression in leukemia cells: application of L-asparaginase treatment for leukemia [abstract]. Blood. 1998;92(suppl 1):400a.
41. Kitoh T, Suzuki T, Nagafuji K, et al. Identification of L-asparaginase-sensitive nasal natural killer/natural killer-like T-cell lymphoma: usefulness of immunostaining result for asparagine synthetase in lymphoma cells [in Japanese]. Ketsueki-Schuyou-ka. 2003;46:108-109.
42. Nagafuji K, Fujisaki T, Arima F, Ohshima K. L-asparaginase induced durable remission of relapsed nasal NK/T-cell lymphoma after autologous peripheral blood stem cell transplantation. Int J Hematol. 2001;74:447-450.
43. Liang R, Chen F, Lee CK, et al. Autologous bone marrow transplantation for primary nasal T/NK cell lymphoma. Bone Marrow Transplant. 1997;19:91-93.
44. Takenaka K, Shinagawa K, Maeda Y, et al. High-dose chemotherapy with hematopoietic stem cell transplantation is effective for nasal-type CD56+ natural killer cell lymphomas. Leuk Lymphoma. 2001;42:1297-1303.
45. Tefferi A, Li C-Y, Witzig TE, Dhodapkar MV, Okuno SH, Phyliky RL. Chronic natural killer cell lymphocytosis: a descriptive clinical study. Blood. 1994;84:2721-2725.
46. - lymphoproliferative disease of granular lymphocytes. Blood. 1993;81:2363-2368.